文献速递传染病防控与疫情报告免疫规划

利什曼原虫A2蛋白疫苗对犬内脏利什曼病的免疫治疗效果随机对照双盲现场试验

Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis.
PubMed 文献 · Vaccine · 2018-09-12

为评估重组利什曼原虫A2蛋白皂苷佐剂疫苗LeishTec®对已感染L. infantum的猎犬的免疫治疗效果,在巴西和地中海盆地开展双盲、区组随机、安慰剂对照现场试验,主要结局为临床进展减少,次要结局为死亡率降低。结果显示无症状犬进展为临床利什曼病的风险降低25%(RR:1.33 95%CI 1.009-1.786 P=0.0450),年轻无症状犬接种疫苗较安慰剂全因死亡率降低70%(RR:3.19 95%CI:1.185-8.502 P=0.0245)。

要点

  • 无症状感染犬接种LeishTec®疫苗后临床进展风险降低25%(RR:1.33 95%CI 1.009-1.786 P=0.0450)。
  • 年轻无症状感染犬接种疫苗较安慰剂全因死亡率降低70%(RR:3.19 95%CI:1.185-8.502 P=0.0245)。
  • 对感染健康犬使用抗利什曼原虫疫苗可显著减少临床进展和全因死亡率。

核心结论

  • 对感染L. infantum的健康犬接种抗利什曼原虫疫苗可显著减少临床进展并降低全因死亡率。
  • 在感染健康犬中使用疫苗接种可作为利什曼原虫控制的工具。

研究设计与样本

  • 双盲、区组随机、安慰剂对照的疫苗免疫治疗试验,对象为感染L. infantum的私家猎犬。
  • 试验疫苗为重组利什曼原虫A2蛋白皂苷佐剂疫苗LeishTec®。
  • 主要结局为临床进展减少,次要结局为死亡率降低。

主要发现

  • 无症状犬接种疫苗作为免疫治疗使进展为临床明显利什曼病的风险降低25%(RR:1.33 95%CI 1.009-1.786 P=0.0450)。
  • 年轻无症状犬接种疫苗较安慰剂全因死亡率降低70%(RR:3.19 95%CI:1.185-8.502 P=0.0245)。

关键数值与推荐

  • 无症状犬临床进展风险降低25%(RR:1.33 95%CI 1.009-1.786 P=0.0450)。
  • 年轻无症状犬全因死亡率降低70%(RR:3.19 95%CI:1.185-8.502 P=0.0245)。

临床怎么用

  • 对感染L. infantum的健康犬可使用抗利什曼原虫疫苗LeishTec®作为免疫治疗以降低临床进展风险。
  • 在年轻无症状感染犬中接种该疫苗可降低全因死亡率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Better tools are necessary to eliminate visceral leishmaniasis (VL). Modeling studies for regional Leishmania elimination indicate that an effective vaccine is a critical tool. Dogs are the reservoir host of L. infantum in Brazil and the Mediterranean basin, and therefore are an important target for public health interventions as well as a relevant disease model for human VL. No vaccine has been efficacious as an immunotherapy to prevent progression of already diagnostically positive individuals to symptomatic leishmaniasis. We performed a double-blinded, block-randomized, placebo-controlled, vaccine immunotherapy trial testing the efficacy of a recombinant Leishmania A2 protein, saponin-adjuvanted, vaccine, LeishTec®, in owned hunting dogs infected with L. infantum. The primary outcome was reduction of clinical progression, with reduction of mortality as a secondary outcome. Vaccination as an immunotherapy reduced the risk of progression to clinically overt leishmaniasis by 25% in asymptomatic dogs (RR: 1.33 95% C.I. 1.009-1.786 p-value: 0.0450). Receiving vaccine vs. placebo reduced all-cause mortality in younger asymptomatic dogs by 70% (RR: 3.19 95% C.I.: 1.185-8.502 p-value = 0.0245). Vaccination of infected-healthy animals with an anti-Leishmania vaccine significantly reduced clinical progression and decreased all-cause mortality. Use of vaccination in infected-healthy dogs can be a tool for Leishmania control.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Toepp A, Larson M, Wilson G, et al. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis. Vaccine. 2018. PMID: 30219369. doi:10.1016/j.vaccine.2018.08.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。